Premium
Type‐2 inflammatory mediators as targets for precision medicine in children
Author(s) -
Castagnoli Riccardo,
Licari Amelia,
Manti Sara,
Chiappini Elena,
Marseglia Gian Luigi
Publication year - 2020
Publication title -
pediatric allergy and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.269
H-Index - 89
eISSN - 1399-3038
pISSN - 0905-6157
DOI - 10.1111/pai.13340
Subject(s) - medicine , atopic dermatitis , immunology , asthma , immunoglobulin e , precision medicine , inflammation , population , disease , interleukin 13 , interleukin , cytokine , antibody , environmental health , pathology
The prevalence, heterogeneity, and severity of type 2 inflammatory diseases, including asthma and atopic dermatitis, continue to rise, especially in children and adolescents. Type 2 inflammation is mediated by both innate and adaptive immune cells and sustained by a specific subset of cytokines, such as interleukin (IL)‐4, IL‐5,IL‐13, and IgE. IL‐4 and IL‐13 are considered signature type 2 cytokines, as they both have a pivotal role in many of the pathobiologic changes featured in asthma and atopic dermatitis. Several biologics targeting IL‐4, IL‐5, and IL‐13, as well as IgE, have been proposed to treat severe allergic disease in the pediatric population with promising results. A better definition of type 2 inflammatory pathways is essential to implement targeted therapeutic strategies.